Clinical Research Directory
Browse clinical research sites, groups, and studies.
Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca
Sponsor: Baylor Research Institute
Summary
CDK4/6 and Cyclin D1 are significantly expressed in approximately 80% of esophageal and gastroesophageal junction tumors suggesting that CDK4/6 inhibition may be a successful strategy in these chemotherapy and immunotherapy resistant diseases.
Official title: Phase I/II Study of Abemaciclib + Ramucirumab in Metastatic Esophageal/Gastroesophageal Junction Carcinomas
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
8
Start Date
2021-06-11
Completion Date
2026-06
Last Updated
2026-02-05
Healthy Volunteers
No
Interventions
Abemaciclib
150mg dose administered orally twice daily every day
Ramucirumab
8mg/kg iv every 2 weeks until evidence of disease
Locations (1)
Baylor University Medical Center, Charles A Sammons Cancer Center
Dallas, Texas, United States